$ 3.33
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of SANA is 9.3 and suggests 178% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
